Literature DB >> 18848173

Plasma visfatin levels in normal weight women with polycystic ovary syndrome.

Dimitrios Panidis1, Dimitrios Farmakiotis, David Rousso, Ilias Katsikis, Dimitrios Delkos, Athanasia Piouka, Spiros Gerou, Evanthia Diamanti-Kandarakis.   

Abstract

BACKGROUND: The present study was designed to measure plasma visfatin levels in normal weight women with polycystic ovary syndrome (PCOS) and to assess possible correlations between visfatin and the hormonal or metabolic parameters of the syndrome.
METHODS: Twenty-five normal weight [body mass index (BMI)<25 kg/m(2)] women with PCOS, 24 obese and overweight (BMI>25 kg/m(2)) controls (ovulating women without clinical or biochemical hyperandrogenism), and 24 normal weight controls were studied. Blood samples were collected between the 3rd and the 7th days of a menstrual cycle in the control groups and during a spontaneous bleeding episode in the PCOS groups at 9:00 A.M., after an overnight fast. Circulating levels of LH, FSH, prolactin (PRL), testosterone (T), Delta(4)-androstenedione (Delta(4)-Alpha), dehydroepiandrosterone sulfate (DHEA-S), 17alpha-OH-progesterone (17OH-P), sex hormone-binding globulin (SHBG), insulin, glucose, and visfatin were measured.
RESULTS: Plasma visfatin levels and the visfatin-to-insulin ratio were significantly lower in normal weight controls than in both normal weight women with PCOS and overweight or obese controls. The visfatin-to-insulin ratio was significantly higher in normal weight women with PCOS than in overweight or obese controls. Plasma visfatin levels were found to be positively correlated with LH and Delta(4)A levels, as well as with free androgen index (FAI) values, and negatively correlated with SHBG. LH and SHBG levels were found to be the only independent significant determinants of circulating visfatin. In the control groups, plasma visfatin levels were significantly correlated with BMI, waist (W) measurement, and waist-to-hip ratio (WHR).
CONCLUSIONS: Visfatin levels are positively associated with obesity in healthy women of reproductive age. Moreover, the present study indicates, for the first time, a possible involvement of increased visfatin levels in PCOS-associated metabolic and hormonal disturbances.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848173     DOI: 10.1016/j.ejim.2007.05.014

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  13 in total

1.  Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis.

Authors:  Yuanhui Duan; Dongsheng Hao; Ming Li; Zhihong Wu; Deling Li; Xinyu Yang; Guixing Qiu
Journal:  Rheumatol Int       Date:  2011-01-19       Impact factor: 2.631

2.  Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome.

Authors:  N Güdücü; H İsçi; U Görmüş; A B Yiğiter; İ Dünder
Journal:  J Endocrinol Invest       Date:  2013-03       Impact factor: 4.256

Review 3.  Mechanisms of obesity-induced metabolic and vascular dysfunctions.

Authors:  Reem T Atawia; Katharine L Bunch; Haroldo A Toque; Ruth B Caldwell; Robert W Caldwell
Journal:  Front Biosci (Landmark Ed)       Date:  2019-03-01

4.  Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome.

Authors:  Magdalena Olszanecka-Glinianowicz; Piotr Kocełak; Marcin Nylec; Jerzy Chudek; Barbara Zahorska-Markiewicz
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

Review 5.  Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women.

Authors:  Dinka Pavicic Baldani; Lana Skrgatic; Roya Ougouag
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

6.  Visfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome.

Authors:  Fatemeh Farshchian; Fahimeh Ramezani Tehrani; Houshang Amirrasouli; Hooman Rahimi Pour; Mehdi Hedayati; Faranak Kazerouni; Adeleh Soltani
Journal:  Int J Endocrinol Metab       Date:  2014-07-01

7.  Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls.

Authors:  Jin Ju Kim; Young Min Choi; Min A Hong; Min Jeong Kim; Soo Jin Chae; Sun Mie Kim; Kyu Ri Hwang; Sang Ho Yoon; Seung Yup Ku; Chang Suk Suh; Seok Hyun Kim
Journal:  Obstet Gynecol Sci       Date:  2018-02-05

Review 8.  Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models.

Authors:  Anthony Estienne; Alice Bongrani; Maxime Reverchon; Christelle Ramé; Pierre-Henri Ducluzeau; Pascal Froment; Joëlle Dupont
Journal:  Int J Mol Sci       Date:  2019-09-09       Impact factor: 5.923

9.  Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandrogenism in polycystic ovary syndrome.

Authors:  Fabio V Comim; Kate Hardy; Stephen Franks
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

10.  Ovarian Expression of Adipokines in Polycystic Ovary Syndrome: A Role for Chemerin, Omentin, and Apelin in Follicular Growth Arrest and Ovulatory Dysfunction?

Authors:  Alice Bongrani; Namya Mellouk; Christelle Rame; Marion Cornuau; Fabrice Guérif; Pascal Froment; Joëlle Dupont
Journal:  Int J Mol Sci       Date:  2019-08-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.